Myriad Genetics Company Profile (NASDAQ:MYGN)

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 6 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $42.83 (33.98% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016MizuhoReiterated RatingNeutral$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Barclays PLCReiterated RatingOverweight$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Bank of America Corp.Reiterated RatingHold$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016Goldman Sachs Group Inc.Boost Price Target$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Deutsche Bank AGReiterated RatingBuy$52.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/27/2015Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/20/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/16/2015StephensBoost Price TargetOverweight$42.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Jefferies GroupBoost Price TargetHold$32.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2015GabelliInitiated CoverageBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Credit Suisse Group AGReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2014Morgan StanleyInitiated CoverageUnderperform -> Underperform$25.00 -> $34.89View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2012$0.34$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012$0.32$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2012$0.31$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011$0.27$0.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011$0.29$0.30ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.25$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$0.26$0.26ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20172$0.42$0.45$0.44
Q2 20171$0.46$0.46$0.46
Q3 20171$0.43$0.43$0.43
Q4 20171$0.38$0.38$0.38
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline
07/21/16 05:39 PMMyriad Genetics, Inc. (NASDAQ:MYGN): Share Synopsis and Trading Review - Press Telegraph
07/21/16 10:33 AMHere's Why Myriad Genetics Is Down 26% in 2016 - A combination of disappointing guidance and increasing competition has resulted in a painful 2016 for Myriad Genetics investors, but there are reasons for optimism.
07/21/16 08:13 AMMyriad Genetics, Inc. (NASDAQ:MYGN) Expected To Post Sales Of $1216 - Investor Newswire
07/20/16 06:04 PMAre Analysts Bearish Myriad Genetics, Inc. (NASDAQ:MYGN) After Last Week? - Consumer Eagle
07/20/16 06:04 PMShares Lower on the Year Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
07/20/16 06:04 PMShares Positive Over the Past Month: Myriad Genetics, Inc. (NASDAQ:MYGN) - TGP
07/18/16 10:40 AMTrading Performance and Target Watch for Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
07/18/16 10:40 AMMyriad Genetics, Inc. (NASDAQ:MYGN) Stock Rating Update - Investor Newswire
07/17/16 04:47 PMReview on Stock Valuation for: Myriad Genetics, Inc. (NASDAQ:MYGN) - TGP
07/17/16 04:47 PMScopia Capital Management LP Decreased Stake in Myriad Genetics INC (NASDAQ:MYGN) by $39.05 Million as ... - Press Telegraph
07/17/16 04:47 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Broker Price Targets For The Coming Week - Fiscal Standard
07/15/16 09:58 AMConsensus Target and Stock Rating Report: Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/14/16 05:36 PMEquity Insight on Myriad Genetics, Inc. (NASDAQ:MYGN) Shares - Telanagana Press
07/14/16 05:36 PMMyriad Genetics Inc Realized Volatility Hits Elevated Level - CML News
07/14/16 08:57 AMCrowd Rating and Earnings Recap for Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/14/16 08:57 AMMyriad Genetics, Inc. (NASDAQ:MYGN) Yearly Sales Target At $1216 - Investor Newswire
07/13/16 08:19 AMAnalyst Target and Average Rating Watch: Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
07/12/16 05:37 PMEquity Review - Shares in Focus: Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/12/16 05:37 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Company Stock Rating in Focus - Engelwood Daily
07/12/16 05:37 PMHow Analysts Feel About Myriad Genetics, Inc. (NASDAQ:MYGN)? - Press Telegraph
07/12/16 05:37 PMStock Down on the Year Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
07/12/16 05:37 PMStocks Active on Selling Boundary- Myriad Genetics (NASDAQ:MYGN), KeyCorp. (NYSE:KEY), Nordstrom (NYSE:JWN) - Seneca Globe
07/12/16 05:37 PMMyriad Genetics (MYGN) Announces Publication of Positive EndoPredict Data in Breast Cancer; Says Primary ... - StreetInsider.com
07/11/16 05:21 PMMYRIAD GENETICS INC
07/11/16 05:21 PMMyriad Genetics (MYGN) Announces Publication of Positive EndoPredict Data in Breast Cancer; Says Primary Endpoint Met
07/11/16 10:43 AMMyriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute - [at noodls] - SALT LAKE CITY and COLOGNE, Germany, July 11, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), in collaboration with researchers from the Institute of Cancer Research in London, today announced ...
07/11/16 09:59 AMFocus Stock Trading Recap : Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/11/16 09:59 AMCompany Shares of Myriad Genetics (NASDAQ:MYGN) Rally 2.99% - TheFounders Daily
07/09/16 04:50 PMIs $50 Within Reach For Myriad Genetics, Inc. (NASDAQ:MYGN)? - Investor Newswire
07/08/16 05:26 PMNews Sentiment and Impact Score Review for :Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
07/08/16 08:16 AMMyriad Genetics, Inc. Stock Momentum Hits Weakness - CML News
07/07/16 05:23 PMMYGN August 26th Options Begin Trading
07/07/16 08:18 AMShares Declining and Worrying Investors: Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/07/16 08:18 AMShort Information Review for: Myriad Genetics, Inc. (NASDAQ:MYGN) - Engelwood Daily
07/05/16 05:09 PMMyriad Genetics, Inc. (NASDAQ:MYGN): Eye on Company Share Performance - Press Telegraph
07/03/16 04:48 PMShare Recap and Performance Review for: Myriad Genetics, Inc. (NASDAQ:MYGN) - Telanagana Press
07/03/16 04:48 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Impact Score and Stock Sentiment Recap - Press Telegraph
07/03/16 09:36 AMBrokers Issue Average Price Target Of 42.92 On Myriad Genetics, Inc. (NASDAQ:MYGN) - Fiscal Standard
07/02/16 05:00 PM1.33 is Myriad Genetics Inc's (NASDAQ:MYGN) Institutional Investor Sentiment - Engelwood Daily
07/01/16 05:22 PMBulls and Bears Call Truces- Shire (NASDAQ:SHPG), Myriad Genetics (NASDAQ:MYGN), Galena Biopharma ... - Seneca Globe
07/01/16 05:22 PMMyriad Genetics myChoice Cancer Test Findings Encourage - Yahoo Finance
07/01/16 08:11 AMMyriad Genetics myChoice Cancer Test Findings Encourage
06/29/16 05:15 PMMyriad Genetics (MYGN) Announces Positive Results for myChoice HRD Test in TESARO (TSRO) Collaboration
06/29/16 08:10 AMmyChoice HRD Increases Eligible Patients by Approximately Twofold
06/29/16 08:10 AMMyriad Genetics' MyChoice HRD Test Identifies Patients With Ovarian Cancer
06/29/16 06:21 AMMyriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib - [at noodls] - SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice HRD test successfully ...
06/29/16 06:15 AMMyriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO’s Pivotal Phase 3 Ovarian Cancer Study with Niraparib - [GlobeNewswire] - SALT LAKE CITY, June 29, 2016-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that its myChoice ® HRD test successfully identified an increased number ...
06/26/16 09:56 AMStock Tracing Lower on the Week Myriad Genetics, Inc. (NASDAQ:MYGN) - Engelwood Daily
06/26/16 09:56 AMStock Performance Focus on: Myriad Genetics, Inc. (NASDAQ:MYGN) - Press Telegraph
06/26/16 09:56 AMStrong Sell Calls Recommendations For Myriad Genetics, Inc. (NASDAQ:MYGN) At 2 - Investor Newswire

Social

About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $32.21
  • 50 Day Moving Average: $31.43
  • 200 Day Moving Average: $35.62
  • P/E Ratio: 21.60
  • P/E Growth: 1.33
  • Market Cap: $2.25B
  • Beta: 0.58
  • Current Year EPS Consensus Estimate: $1.65 EPS
  • Next Year EPS Consensus Estimate: $1.78 EPS
Additional Links:
Myriad Genetics (NASDAQ:MYGN) Chart for Saturday, July, 23, 2016